Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · see citing works

The immune contexture in human tumours: impact on clinical outcome

Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · see citing works

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071 · see citing works

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

Templeton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F., Aneja, P., Ocaña, A., Leibowitz‐Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 3,304 · see citing works

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301 · see citing works

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286 · see citing works

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119 · see citing works

Roles of the immune system in cancer: From tumor initiation to metastatic progression

Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111 · see citing works

Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis

Popat, S., Hubner, R. A., & Houlston, R. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.086 · Cited by 1,830 · see citing works

Adoptive immunotherapy for cancer: harnessing the T cell response

Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688 · see citing works

The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer

Guthrie, G. J. K., Charles, K. A., Roxburgh, C. S. D., Horgan, P. G., McMillan, D. C., & Clarke, S. J. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.03.010 · Cited by 1,566 · see citing works

Neutrophils escort circulating tumour cells to enable cell cycle progression

Szczerba, B. M., Castro-Giner, F., Vetter, M. H. F., Krol, I., Gkountela, S., Landin, J., Scheidmann, M. C., Donato, C., Scherrer, R., Singer, J., et al. (2019) · Nature · doi:10.1038/s41586-019-0915-y · Cited by 1,225 · see citing works

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142 · see citing works

Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer

Walsh, S. R., Cook, E. J., Goulder, F., Justin, T. A., & Keeling, N. J. (2005) · Journal of Surgical Oncology · doi:10.1002/jso.20329 · Cited by 1,121 · see citing works

Tumour-associated neutrophils in patients with cancer

Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,044 · see citing works

Classification and characterization of microsatellite instability across 18 cancer types

Hause, R. J., Pritchard, C. C., Shendure, J., & Salipante, S. J. (2016) · Nature Medicine · doi:10.1038/nm.4191 · Cited by 982 · see citing works

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

Weber, R., Fleming, V., Hu, X., Nagibin, V. S., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 535 · see citing works

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

Bagley, S. J., Kothari, S., Aggarwal, C., Bauml, J. M., Alley, E. W., Evans, T. L., Kosteva, J. A., Ciunci, C. A., Gabriel, P. E., Thompson, J. C., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.01.013 · Cited by 512 · see citing works

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Capone, M., Giannarelli, D., Mallardo, D., Madonna, G., Festino, L., Grimaldi, A. M., Vanella, V., Simeone, E., Paone, M., Palmieri, G., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0383-1 · Cited by 497 · see citing works

Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer

Stotz, M., Gerger, A., Eisner, F., Szkandera, J., Loibner, H., Ress, A. L., Kornprat, P., Zoughbi, W. A., Seggewies, F., Lackner, C., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.332 · Cited by 490 · see citing works

Usefulness of the Neutrophil-to-Lymphocyte Ratio in Predicting Short- and Long-Term Mortality in Breast Cancer Patients

Azab, B., Bhatt, V. R., Phookan, J., Murukutla, S., Kohn, N., Terjanian, T., & Widmann, W. D. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1814-0 · Cited by 447 · see citing works

On the dual roles and polarized phenotypes of neutrophils in tumor development and progression

Piccard, H., Muschel, R. J., & Opdenakker, G. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.06.004 · Cited by 369 · see citing works

Tumor-Associated Neutrophils as a New Prognostic Factor in Cancer: A Systematic Review and Meta-Analysis

Shen, M., Hu, P., Donskov, F. N., Wang, G., Liu, Q., & Du, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098259 · Cited by 348 · see citing works

Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy

Chowell, D., Krishna, C., Pierini, F., Makarov, V., Rizvi, N. A., Kuo, F., Morris, L. G. T., Riaz, N., Lenz, T. L., & Chan, T. A.-T. (2019) · Nature Medicine · doi:10.1038/s41591-019-0639-4 · Cited by 309 · see citing works

Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells

Moses, K., & Brandau, S. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.018 · Cited by 306 · see citing works

Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer

Cedrés, S., Torrejon, D. Y., Martínez‐Martí, A., Martínez, P., Navarro, A., Zamora, E., Mulet-Margalef, N., & Felip, E. (2012) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0872-5 · Cited by 292 · see citing works

Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma

Lalani, A. A., Xie, W., Martini, D. J., Steinharter, J. A., Norton, C. K., Krajewski, K. M., Duquette, A., Bossé, D., Joaquim Bellmunt, B., Allen, E. M. V., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0315-0 · Cited by 269 · see citing works

Unique pattern of neutrophil migration and function during tumor progression

Patel, S., Fu, S., Mastio, J., Dominguez, G. A., Purohit, A., Kossenkov, A. V., Lin, C., Alicea-Torres, K. M., Sehgal, M., Nefedova, Y., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0229-5 · Cited by 222 · see citing works

Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer

Anagnostou, V., Niknafs, N., Marrone, K. A., Bruhm, D. C., White, J. R., Naidoo, J., Hummelink, K., Monkhorst, K., Lalezari, F., Lanis, M. R., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0008-8 · Cited by 196 · see citing works

Neutrophil Heterogeneity in Cancer: From Biology to Therapies

Lecot, P., Sarabi, M., Pereira-Abrantes, M., Mussard, J., Koenderman, L., Caux, C., Bendriss‐Vermare, N., & Michallet, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02155 · Cited by 171 · see citing works

The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced‐stage cancer treated with immunotherapy

Bilen, M. A., Martini, D. J., Liu, Y., Lewis, C. M., Collins, H., Shabto, J. M., Akce, M., Kissick, H. T., Carthon, B. C., Shaib, W. L., et al. (2018) · Cancer · doi:10.1002/cncr.31778 · Cited by 167 · see citing works

PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling

Sprouse, M. L., Welte, T., Boral, D., Liu, H. N., Yin, W., Vishnoi, M., Goswami-Sewell, D., Li, L., Pei, G., Jia, P., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081916 · Cited by 161 · see citing works

Correlations between microsatellite instability and the biological behaviour of tumours

Yang, G. Y., Zheng, R.-Y., & Jin, Z. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03053-4 · Cited by 159 · see citing works

High neutrophil‐to‐lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD‐1 inhibitor monotherapy

Bartlett, E. K., Flynn, J. R., Panageas, K. S., Ferraro, R., Sta.Cruz, J. M., Postow, M. A., Coit, D. G., & Ariyan, C. E. (2019) · Cancer · doi:10.1002/cncr.32506 · Cited by 142 · see citing works

Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival

Cummings, M., Merone, L., Keeble, C. M., Burland, L., Grzelinski, M., Sutton, K., Begum, N., Thacoor, A. S., Green, B., Sarveswaran, J., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.200 · Cited by 128 · see citing works

Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer

Ohki, S., Shibata, M., Gonda, K., Machida, T., Shimura, T., Nakamura, I., Ohtake, T., Koyama, Y., Suzuki, S., Ohto, H., et al. (2012) · Oncology Reports · doi:10.3892/or.2012.1812 · Cited by 119 · see citing works

Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers

Li, M., Spakowicz, D. J., Burkart, J. T., Patel, S. P., Husain, M., He, K., Bertino, E. M., Shields, P. G., Carbone, D. P., Verschraegen, C. F., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02982-4 · Cited by 117 · see citing works

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer

Negrao, M. V., Lam, V. K. L., Reuben, A., Rubin, M. L., Landry, L. L., Roarty, E. B., Rinsurongkawong, W., Lewis, J., Roth, J. A., Swisher, S. G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.008 · Cited by 113 · see citing works

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment

Cassidy, M. R., Wolchok, R. E., Zheng, J., Panageas, K. S., Wolchok, J. D., Coit, D. G., Postow, M. A., & Ariyan, C. E. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.03.029 · Cited by 105 · see citing works

Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non–Small-Cell Lung Cancer: A Prospective Observational Study

Fukui, T., Okuma, Y., Nakahara, Y., Otani, S., Igawa, S., Katagiri, M., Mitsufuji, H., Kubota, M., Hiyoshi, Y., Ishihara, M., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.04.021 · Cited by 99 · see citing works

Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis

Jin, J., Yang, L., Liu, D., & Li, W. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-035031 · Cited by 96 · see citing works

How neutrophils promote metastasis

Tüting, T., & de Visser, K. E. (2016) · Science · doi:10.1126/science.aaf7300 · Cited by 87 · see citing works

Comprehensive assessment of the prognosis of pancreatic cancer: peripheral blood neutrophil–lymphocyte ratio and immunohistochemical analyses of the tumour site

Takakura, K., Ito, Z., Suka, M., Kanai, T., Matsumoto, Y., Odahara, S., Matsudaira, H., Haruki, K., Fujiwara, Y., Saito, R., et al. (2015) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1121515 · Cited by 83 · see citing works

A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma

Nassar, A. H., Mouw, K. W., Jegede, O. A., Shinagare, A. B., Kim, J., Liu, C., Pomerantz, M. M., Harshman, L. C., Allen, E. M. V., Wei, X. X., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0686-0 · Cited by 76 · see citing works

Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy

Lee, M., Samstein, R. M., Valero, C., Chan, T. A.-T., & Morris, L. G. T. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1631136 · Cited by 75 · see citing works

Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?

Marino, F. Z., Ascierto, P. A., Rossi, G., Staibano, S., Montella, M., Russo, D., Alfano, R., Morabito, A., Botti, G., & Franco, R. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1309387 · Cited by 73 · see citing works

Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.

Ameratunga, M., Chénard-Poirier, M., Candilejo, I. M., Pedregal, M., Lui, A., Dolling, D., Aversa, C., Garces, A. I. I., Ang, J., Banerji, U., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.11.012 · Cited by 73 · see citing works

A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies

Cao, D., Xu, H., Xu, X., Guo, T., & Ge, W. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1507262 · Cited by 72 · see citing works

Pretreatment peripheral blood leukocytes are independent predictors of survival in oral cavity cancer

Valero, C., Zanoni, D. K., McGill, M. R., Ganly, I., Morris, L. G. T., Quer, M., Shah, J. P., Wong, R. J., León, X., & Patel, S. G. (2019) · Cancer · doi:10.1002/cncr.32591 · Cited by 64 · see citing works

Prognostic values of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in endometrial cancer: a systematic review and meta-analysis

Ni, L., Tao, J., Xu, J., Yuan, X., Long, Y., Yu, N. H., Wu, R., & Zhang, Y. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05372-w · Cited by 56 · see citing works

Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta‐analysis

Tan, Q., Liu, S., Liang, C., Han, X., & Shi, Y. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12815 · Cited by 49 · see citing works

Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors

Xie, X., Liu, J., Yang, H., Chen, H., Zhou, S., Lin, H., Liao, Z., Ding, Y., Ling, L., & Wang, X. (2019) · Cancer Investigation · doi:10.1080/07357907.2019.1639057 · Cited by 44 · see citing works

Circulating tumor cells promote the metastatic colonization of disseminated carcinoma cells by inducing systemic inflammation

Li, Y., Zou, J.-M., Luo, C., Shu, Y., Luo, J., Qin, J., Wang, Y., Li, D., Wang, S., Chi, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16084 · Cited by 37 · see citing works

Predictive potential and need for standardization of PD-L1 immunohistochemistry

Prince, S. S., & Bubendorf, L. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2445-7 · Cited by 37 · see citing works

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

Passaro, A., Bakir, M. A., Hamilton, E. G., Diehn, M., André, F., Roy‐Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 703 · see citing works

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

McCulloch, J. A., Davar, D., Rodrigues, R. R., Badger, J. H., Fang, J. R., Cole, A. M., Balaji, A. K., Vetizou, M., Prescott, S. M., Fernandes, M. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01698-2 · Cited by 472 · see citing works

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

Chowell, D., Yoo, S., Valero, C., Pastore, A., Krishna, C., Lee, M., Hoen, D. R., Shi, H., Kelly, D. W., Patel, N., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01070-8 · Cited by 265 · see citing works

TMB or not TMB as a biomarker: That is the question

Addeo, A., Friedlaender, A., Banna, G. L., & Weiss, G. J. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103374 · Cited by 220 · see citing works

Immune Checkpoint Inhibitor Therapy in Oncology

Tan, S., Day, D., Nicholls, S. J., & Segelov, E. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.09.004 · Cited by 215 · see citing works

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy

Hwang, M., Canzoniero, J. V., Rosner, S., Zhang, G., White, J. R., Belcaid, Z., Cherry, C., Balan, A., Pereira, G., Curry, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004688 · Cited by 150 · see citing works

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

Guo, C. W., Sharp, A., Gürel, B., Crespo, M., Figueiredo, I., Jain, S., Vogl, U. M., Rekowski, J., Rouhifard, M., Gallagher, L., et al. (2023) · Nature · doi:10.1038/s41586-023-06696-z · Cited by 145 · see citing works

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Wang, Y., Johnson, K. C. C., Gatti-Mays, M. E., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01335-y · Cited by 135 · see citing works

Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data

Yoo, S., Fitzgerald, C. W. R., Cho, B. A., Fitzgerald, B. G., Han, C. Y., Koh, E. S., Pandey, A., Sfreddo, H. J., Crowley, F., Rudshteyn, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03398-5 · Cited by 139 · see citing works

Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy

Raskov, H., Orhan, A., Gaggar, S., & Gögenür, I. (2022) · Oncogenesis · doi:10.1038/s41389-022-00398-3 · Cited by 135 · see citing works

Systemic Immune–Inflammation Index Predicts Prognosis of Cancer Immunotherapy: Systemic Review and Meta-Analysis

Tian, B., Yang, Y., Yang, C., Yan, L., Ding, Z., Liu, H., Xue, J.-S., Dong, Z., Chen, Z., Hong, J., et al. (2022) · Immunotherapy · doi:10.2217/imt-2022-0133 · Cited by 129 · see citing works

LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features

Chang, T., Cao, Y., Sfreddo, H. J., Dhruba, S. R., Lee, S., Valero, C., Yoo, S., Chowell, D., Morris, L. G. T., & Ruppin, E. (2024) · Nature Cancer · doi:10.1038/s43018-024-00772-7 · Cited by 135 · see citing works

The role of biomarkers in personalized immunotherapy

Sankar, K., Ye, J. C., Li, Z., Zheng, L., Song, W., & Hu-Lieskovan, S. (2022) · Biomarker Research · doi:10.1186/s40364-022-00378-0 · Cited by 111 · see citing works

Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer

Alessi, J. V., Ricciuti, B., Alden, S. L., Bertram, A. A., Lin, J. J., Sakhi, M., Nishino, M., Vaz, V. R., Lindsay, J. R., Turner, M. M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003536 · Cited by 103 · see citing works

Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non‐small cell lung cancer patients with neoadjuvant immunotherapy

Huai, Q., Luo, C., Song, P., Bie, F., Bai, G., Li, Y., Liu, Y., Chen, X., Zhou, B., Sun, X., et al. (2023) · Cancer Science · doi:10.1111/cas.15964 · Cited by 102 · see citing works

The GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure

Wu, V. H., Yung, B. S., Faraji, F., Saddawi‐Konefka, R., Wang, Z., Wenzel, A. T., Song, M., Pagadala, M. S., Clubb, L. M., Chiou, J., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01529-7 · Cited by 98 · see citing works

Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities

Wang, X., Lamberti, G., Federico, A. D., Alessi, J. V., Ferrara, R., Sholl, M. L., Awad, M. M., Vokes, N. I., & Ricciuti, B. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.03.007 · Cited by 94 · see citing works

Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma

Mahmood, M., Liu, E. M., Shergold, A. L., Tolla, E., Tait-Mulder, J., Uribe, A. H., Shokry, E., Young, A. L., Lilla, S., Kim, M., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00721-w · Cited by 99 · see citing works

Association between immune-related adverse event timing and treatment outcomes

Hsiehchen, D., Naqash, A. R., Espinoza, M., von Itzstein, M. S., Cortellini, A., Ricciuti, B., Owen, D. H., Laharwal, M., Toi, Y., Burke, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.2017162 · Cited by 93 · see citing works

Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond

Mosca, M., Nigro, M. C., Pagani, R., Giglio, A. D., & Federico, A. D. (2023) · Biomolecules · doi:10.3390/biom13121803 · Cited by 95 · see citing works

The evolution and heterogeneity of neutrophils in cancers: origins, subsets, functions, orchestrations and clinical applications

Liu, S., Wu, W., Du, Y., Yin, H., Chen, Q., Yu, W., Wang, W., Yu, J., Liu, L., Lou, W., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01843-6 · Cited by 92 · see citing works

Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer

Kiviaho, A., Eerola, S. K., Kallio, H. M. L., Andersen, M. K., Hoikka, M., Tiihonen, A. M., Salonen, I., Spotbeen, X., Giesen, A., Parker, C. T. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54364-1 · Cited by 93 · see citing works

Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity

Ma, X., Riaz, N., Samstein, R. M., Lee, M. A., Makarov, V., Valero, C., Chowell, D., Kuo, F., Hoen, D. R., Fitzgerald, C. W. R., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01108-w · Cited by 84 · see citing works

Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF V600E -Mutated Anaplastic Thyroid Carcinoma

Hamidi, S., Iyer, P. C., Dadu, R., Gule-Monroe, M. K., Maniakas, A., Zafereo, M., Wang, J. R., Busaidy, N. L., & Cabanillas, M. E. (2024) · Thyroid · doi:10.1089/thy.2023.0573 · Cited by 84 · see citing works

γδ T Cells in the Tumor Microenvironment—Interactions With Other Immune Cells

Chan, K. F., Duarte, J. D. G., Ostrouska, S., & Behren, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.894315 · Cited by 77 · see citing works

KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup

Xie, M., Xu, X., & Fan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672612 · Cited by 76 · see citing works

Distinct Mechanisms of Mismatch Repair Deficiency Delineate Two Modes of Response to PD-1 Immunotherapy in Endometrial Carcinoma

Chow, R. D.-W., Michaels, T., Bellone, S., Hartwich, T. M. P., Bonazzoli, E., Iwasaki, A., Song, E., & Santin, A. D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0686 · Cited by 74 · see citing works

Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors

Wang, J., Ma, Y., Lin, H., Wang, J., & Cao, B. (2024) · BMC Immunology · doi:10.1186/s12865-024-00599-y · Cited by 72 · see citing works

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer

Daniello, L., Elshiaty, M., Bozorgmehr, F., Kuon, J., Kazdal, D. N., Schindler, H., Shah, R., Volckmar, A., Lusky, F., Diekmann, L., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703893 · Cited by 68 · see citing works

Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy

Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 73 · see citing works

Baseline and early changes in the neutrophil–lymphocyte ratio (NLR) predict survival outcomes in advanced colorectal cancer patients treated with immunotherapy

Ouyang, H., Xiao, B., Huang, Y., & Wang, Z. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110703 · Cited by 68 · see citing works

Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial

Vos, J. L., Burman, B., Jain, S., Fitzgerald, C. W. R., Sherman, E. J., Dunn, L. A., Fetten, J. V., Michel, L. S., Kriplani, A., Ng, K., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02518-x · Cited by 62 · see citing works

The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study

Li, C., Wu, J., Jiang, L., Zhang, L., Huang, J., Tian, Y., Zhao, Y., Liu, X., Xia, L., Haoran, E., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03262-w · Cited by 60 · see citing works

Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?

Splendiani, E., Besharat, Z. M., Covre, A., Maio, M., Giacomo, A. M. D., & Ferretti, E. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108613 · Cited by 62 · see citing works

Neutrophil‐to‐lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta‐analysis

Takenaka, Y., Oya, R., Takemoto, N., & Inohara, H. (2022) · Head & Neck · doi:10.1002/hed.26997 · Cited by 60 · see citing works

Thyroid-related adverse events induced by immune checkpoint inhibitors

Chera, A., Stancu, A. L., & Bucur, O. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1010279 · Cited by 61 · see citing works

Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors

Zarif, T. E., Nassar, A. H., Pond, G. R., Zhuang, T., Master, V. A., Nazha, B., Niglio, S. A., Simon, N. I., Hahn, A. W., Pettaway, C. A., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad155 · Cited by 60 · see citing works

Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real‐world cohort

Jost‐Brinkmann, F., Demir, M., Wree, A., Luedde, T., Loosen, S. H., Müller, T., Tacke, F., Roderburg, C., & Mohr, R. U. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17441 · Cited by 59 · see citing works

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades

Zhao, X., Bao, Y., Meng, B., Xu, Z., Li, S., Wang, X., Hou, R., Ma, W., Liu, D., Zheng, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.920021 · Cited by 57 · see citing works

Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures

Wei, F., Azuma, K., Nakahara, Y., Saito, H., Matsuo, N., Tagami, T., Kouro, T., Igarashi, Y., Tokito, T., Kato, T., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006788 · Cited by 56 · see citing works

Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review

Guo, Y., Xiang, D., Wan, J., Yang, L., & Zheng, C. (2022) · Cancers · doi:10.3390/cancers14215297 · Cited by 62 · see citing works

Association of high-risk stigmata and worrisome features with advanced neoplasia in intraductal papillary mucinous neoplasms (IPMN): A systematic review

Ohno, E., Balduzzi, A., Hijioka, S., Pastena, M. D., Marchegiani, G., Kato, H., Takenaka, M., Haba, S., & Salvia, R. (2023) · Pancreatology · doi:10.1016/j.pan.2023.12.002 · Cited by 55 · see citing works

Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis

Su, J., Yu-ning, L., Tan, S., Cheng, T., Luo, Y., & Zhang, L. (2025) · Scientific Reports · doi:10.1038/s41598-024-84890-3 · Cited by 60 · see citing works

Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols

Cottrell, T. R., Lotze, M. T., Ali, A. M., Bifulco, C. B., Capitini, C. M., Chow, L. Q. M., Cillo, A. R., Collyar, D. E., Cope, L., Deutsch, J. S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010928 · Cited by 61 · see citing works

Immunomodulatory effects of G-CSF in cancer: Therapeutic implications

Mouchemore, K. A., & Anderson, R. L. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101512 · Cited by 55 · see citing works

Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition

Alvarez-Breckenridge, C. A., Markson, S. C., Stocking, J. H., Nayyar, N., Lastrapes, M., Strickland, M. R., Kim, A. E., de Sauvage, M. A., Dahal, A., Larson, J. M., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0870 · Cited by 54 · see citing works

Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back

Mariniello, A., Borgeaud, M., WEINER, M. H., Frisone, D., Kim, F., & Addeo, A. (2025) · BioDrugs · doi:10.1007/s40259-024-00700-2 · Cited by 58 · see citing works

Versatile neutrophil functions in cancer

Siwicki, M. R., & Pittet, M. J. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101538 · Cited by 51 · see citing works

Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study

Qu, S., Zhang, X., Wu, Y., Meng, Y., Pan, H., Fang, Q., Hu, L., Zhang, J., Wang, R., Wei, L., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.874473 · Cited by 52 · see citing works

Immunotherapy-related biomarkers: Confirmations and uncertainties

Catalano, M., Iannone, L. F., Nesi, G., Nobili, S., Mini, E., & Roviello, G. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104135 · Cited by 54 · see citing works

Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer

Chen, Y., Wen, S., Xia, J., Du, X., Wu, Y., Pan, B., Zhu, W., & Shen, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672271 · Cited by 51 · see citing works

Progresses in biomarkers for cancer immunotherapy

Lin, X., Zong, C., Zhang, Z., Fang, W., & Xu, P. (2023) · MedComm · doi:10.1002/mco2.387 · Cited by 48 · see citing works

Tumor-associated neutrophils suppress CD8+ T cell immunity in urothelial bladder carcinoma through the COX-2/PGE2/IDO1 Axis

Ouyang, Y., Zhong, W., Xu, P., Wang, B., Zhang, L., Yang, M., Chen, J., Li, H., Li, S., Chen, X., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-023-02552-z · Cited by 47 · see citing works

Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types

Sinha, N., Sinha, S., Valero, C., Schäffer, A. A., Aldape, K., Litchfield, K., Chan, T. A., Morris, L. G. T., & Ruppin, E. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2542 · Cited by 49 · see citing works

Abscopal Effects of Local Radiotherapy Are Dependent on Tumor Immunogenicity

Lai, J., Zhu, Y., Liu, Y., Zhou, L., Hu, L., Chen, L., & Zhang, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.690188 · Cited by 46 · see citing works

Targeting neutrophils for cancer therapy

Kwak, J., & Houghton, A. M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01210-8 · Cited by 51 · see citing works

Systemic and local immunosuppression in glioblastoma and its prognostic significance

Stepanenko, A. A., Sosnovtseva, A. O., Valikhov, M. P., Chernysheva, A. A., Abramova, O. V., Ka, P., & Chekhonin, V. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1326753 · Cited by 46 · see citing works

Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis

Chuma, M., Uojima, H., Hattori, N., Arase, Y., Fukushima, T., Hirose, S., Kobayashi, S., Ueno, M., Tezuka, S., Iwasaki, S., et al. (2021) · Hepatology Research · doi:10.1111/hepr.13732 · Cited by 44 · see citing works

Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer

Hecht, M., Eckstein, M., Rutzner, S., von der Grün, J., Illmer, T., Klautke, G., Laban, S. A., Hautmann, M., Brunner, T. B., Tamaskovics, B. F., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003747 · Cited by 44 · see citing works

Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade

Yoo, S., Chowell, D., Valero, C., Morris, L. G. T., & Chan, T. A.-T. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00267-7 · Cited by 43 · see citing works

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

Farina, B., Ramos-Guerra, A. D., Bermejo-Peláez, D., Miras, C. P., Peral, A. A., Madueño, G. G., Jaime, J. C., Vilalta, A., Rubio, J., Muñoz‐Barrutia, A., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04004-x · Cited by 43 · see citing works

Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients

Zhou, X., Zhou, L., Yao, Z., Huang, M., Gong, Y., Zou, B., Zhu, J., Liu, Y., Peng, F., Zhang, Y., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0315 · Cited by 41 · see citing works

The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study

Yi, L., Ning, Z., Xu, L., Shen, Y. L., Zhu, X., Yu, W., Xie, J., & Meng, Z. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102239 · Cited by 41 · see citing works

Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer

Bryant, A. K., Sankar, K. N., Strohbehn, G. W., Zhao, L., Elliott, D., Qin, A., Yentz, S. E., Ramnath, N., & Green, M. D. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.11.021 · Cited by 39 · see citing works

Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

Thummalapalli, R., Ricciuti, B., Bandlamudi, C., Muldoon, D. M., Rizvi, H. A., Elkrief, A., Luo, J., Alessi, J. V., Pecci, F., Lamberti, G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1207 · Cited by 38 · see citing works

Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLC

Horvath, L., Puschmann, C., Scheiber, A., Martowicz, A., Sturm, G., Trajanoski, Z., Wolf, D. G. F., Pircher, A., & Salcher, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.01.010 · Cited by 38 · see citing works

Association of systemic inflammatory markers and tertiary lymphoid structure with pathological complete response in gastric cancer patients receiving preoperative treatment: a retrospective cohort study

Wu, Y., Zhao, J., Wang, Z., Liu, D., Tian, C., Ye, B., Sun, Y., Li, H., & Wang, X. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000741 · Cited by 37 · see citing works

The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients

Lu, M., Xu, J., Ye, Y., Wang, Y., Luo, S., & Gong, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.723609 · Cited by 36 · see citing works

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

Bilen, M. A., Rini, B. I., Voss, M. H., Larkin, J., Haanen, J. B. A. G., Albiges, L. K., Pagliaro, L. C., Voog, É., Lam, E. T., Kislov, N. V., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1688 · Cited by 36 · see citing works

Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment

Gianni, C., Palleschi, M., Schepisi, G., Casadei, C., Bleve, S., Merloni, F., Sirico, M., Sarti, S., Cecconetto, L., Menna, G. D., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.882896 · Cited by 38 · see citing works

Circulating and Tumor-Associated Neutrophils in the Era of Immune Checkpoint Inhibitors: Dynamics, Phenotypes, Metabolism, and Functions

Gibellini, L., Borella, R., Santacroce, E., Serattini, E., Boraldi, F., Quaglino, D., Aramini, B., Biasi, S. D., & Cossarizza, A. (2023) · Cancers · doi:10.3390/cancers15133327 · Cited by 35 · see citing works

A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma

Rappold, P. M., Vuong, L. H., Leibold, J., Chakiryan, N. H., Curry, M., Kuo, F., Sabio, E. Y., Jiang, H., Nixon, B. G., Liu, M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0925 · Cited by 35 · see citing works

Pretrained transformers applied to clinical studies improve predictions of treatment efficacy and associated biomarkers

(2025) · doi:10.1038/s41467-025-57181-2 · Cited by 34 · see citing works

Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?

Lelliott, E. J., Sheppard, K. E., & McArthur, G. A. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00273-9 · Cited by 34 · see citing works

Associations between systemic inflammation indicators and nonalcoholic fatty liver disease: evidence from a prospective study

Gong, H., He, Q., Zhu, L., Feng, Z., Sun, M., Jiang, J., Yuan, X., Shen, Y., & Di, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1389967 · Cited by 33 · see citing works

Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort

Qi, W., Wang, X., Li, C., Li, S., Li, H., Xu, F., Chen, J., Zhao, S., & Li, H. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14898 · Cited by 33 · see citing works

Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial

Cortellini, A., Ricciuti, B., Borghaei, H., Naqash, A. R., D’Alessio, A., Fulgenzi, C. A. M., Addeo, A., Banna, G. L., & Pinato, D. J. (2022) · Cancer · doi:10.1002/cncr.34348 · Cited by 31 · see citing works

Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study

Zheng, F., Meng, Q., Zhang, L., Chen, J., Zhao, L., Zhou, Z., & Liu, Y. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03077-8 · Cited by 30 · see citing works

Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors

Liu, C., Zhao, H., Zhang, R., Guo, Z., Wang, P., & Qu, Z.-W. (2023) · Oncology Letters · doi:10.3892/ol.2023.14024 · Cited by 31 · see citing works

Challenges and Future Directions in the Management of Tumor Mutational Burden-High (TMB-H) Advanced Solid Malignancies

Ahmed, J., Das, B., Shin, S. J., & Chen, A. P. (2023) · Cancers · doi:10.3390/cancers15245841 · Cited by 32 · see citing works

Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent

Albarrán, V., Guerrero, P., de Quevedo, C. G., González-Merino, C., Chamorro, J. V., Rosero, D. I., Moreno, J., Calvo, J. C., de Aguado, P. P., Alía, V., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03772-9 · Cited by 30 · see citing works

Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study

Yang, K., Han, L., Wu, S., Qu, X., Li, Q., Zhao, C., Zhou, J., Jin, X. S., Wang, Y., Dong, Y., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03083-3 · Cited by 30 · see citing works

Neutrophils: Musketeers against immunotherapy

Zahid, K. R., Raza, U., Tumbath, S., Jiang, L., Xu, W., & Huang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.975981 · Cited by 30 · see citing works

Fibrinogen-like 2 in tumor-associated macrophage-derived extracellular vesicles shapes an immunosuppressive microenvironment in colorectal liver metastases by promoting tumor stemness and neutrophil extracellular traps formation

Zhou, M., Guan, B., Liu, Y., Gu, Q., Chen, W. T., Xie, B., Zhou, M., Xiang, J., Zhao, S., Zhao, Q., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217642 · Cited by 29 · see citing works

Nomogram Based on Inflammatory Biomarkers and Nutritional Indicators for Predicting Overall Survival in Locoregionally Advanced Nasopharyngeal Carcinoma

Zhao, R., Liang, Z., Chen, K.-H., & Zhu, X. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s366299 · Cited by 29 · see citing works

Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy

Halima, A., Vuong, W., & Chan, T. A.-T. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154945 · Cited by 29 · see citing works

Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With Pembrolizumab

Romano, F. J., Ronga, R., Ambrosio, F., Arundine, D., Longo, V., Galetta, D., Gridelli, C., Maione, P., PALMA, V., Damiano, V., et al. (2022) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10178 · Cited by 28 · see citing works

Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer

Qiu, X., Shi, Z., Tong, F., Lu, C., Zhu, Y., Wang, Q.-L., Gu, Q., Qian, X., Meng, F., Liu, B., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2178791 · Cited by 28 · see citing works

Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity

Zheng, M. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006462 · Cited by 28 · see citing works

Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events

Meybodi, S. M., Far, B. F., Pourmolaei, A., Baradarbarjastehbaf, F., Safaei, M., Mohammadkhani, N., & Samadani, A. A. (2023) · Medical Oncology · doi:10.1007/s12032-023-02114-6 · Cited by 28 · see citing works

The neutrophil–lymphocyte ratio: considerations for clinical application

Adamstein, N. H., & Ridker, P. M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab166 · Cited by 27 · see citing works

Overcoming anti-PD-1/PD-L1 immune checkpoint blockade resistance: the role of macrophage, neutrophils and mast cells in the tumor microenvironment

Kwantwi, L. B. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01059-4 · Cited by 27 · see citing works

Javelin Head Neck 100: Should we combine immunotherapy with radiation therapy?

Yu, Y., Zakeri, K., & Lee, N. (2021) · Oncotarget · doi:10.18632/oncotarget.27987 · Cited by 27 · see citing works

Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer

Gómez-Banoy, N., Ortiz, E. J., Jiang, C. S., Dagher, C., Sevilla, C., Girshman, J., Pagano, A., Plodkowski, A. J., Zammarrelli, W. A., Mueller, J. J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180516 · Cited by 30 · see citing works

Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy

Wang, T., Denman, D., Bacot, S. M., & Feldman, G. M. (2022) · Biomedicines · doi:10.3390/biomedicines10051181 · Cited by 26 · see citing works

Prognostic Effect of the Controlling Nutritional Status Score in Patients With Esophageal Cancer Treated With Immune Checkpoint Inhibitor

Chang, L., Cheng, Q., Ma, Y., Wu, C., Zhang, X., Ma, Q., He, L., Li, Q., & Ji, T. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000438 · Cited by 26 · see citing works

Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment

Wan, M., Ding, Y., Mao, C., Ma, X., Li, N., Cheng, X., Qian, J., Jiang, H., Zheng, Y., Wu, L., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1029960 · Cited by 26 · see citing works

Prolonged survival of anaplastic thyroid carcinoma is associated with resectability, low tumor-infiltrating neutrophils/myeloid-derived suppressor cells, and low peripheral neutrophil-to-lymphocyte ratio

Xu, B., Zhang, L., Setoodeh, R., Mohanty, A. S., Landa, I., Balzer, B. L., Tiedje, V., Ganly, I., Doğan, S., Fagin, J. A., et al. (2022) · Endocrine · doi:10.1007/s12020-022-03008-9 · Cited by 24 · see citing works

High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study

Brocco, D., Bellis, D. D., Marino, P. D., Simeone, P., Grassadonia, A., Tursi, M. D., Grottola, T., di Mola, F. F., Gregorio, P. D., Zappacosta, B., et al. (2022) · Cancers · doi:10.3390/cancers14194748 · Cited by 24 · see citing works

Senescent neutrophils: a hidden role in cancer progression

Rys, R. N., & Calcinotto, A. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.09.001 · Cited by 25 · see citing works

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictor of Survival and Response to Therapy in Patients Treated with Immune Checkpoint InhibitorsPreprint

Valero, C., Lee, M. A., Hoen, D. R., Weiss, K. L., Kelly, D. J., Adusumilli, P. S., Paik, P. K., Plitas, G., Ladanyi, M., Postow, M. A., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3578798

High pretreatment neutrophil-to-lymphocyte ratio (NLR) and its reactive increase as better predictors of poor clinical outcomes compared to tumor mutation burden (TMB) in solid tumor patients treated with immune checkpoint inhibitors (ICI).

Florou, V., Park, W., Torres, A. E., Algaze, S. D., Saravia, D., Wilky, B. A., Merchan, J. R., Hosein, P. J., Lockhart, A. C., & Junior, G. L. L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e24109

Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis

Sacdalan, D. B., Lucero, J. A., & Sacdalan, D. L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s153290 · Cited by 307 · see citing works

481P The predictive role of neutrophil-to-lymphocyte ratio in patients with solid cancers treated with immune checkpoint inhibitors: A pooled analysis of seven clinical trials of the German AIO study group

Dreikhausen, L., Wiest, I., Keller, R., Marin-Galiano, M., Darr, C., Stein, A., Binder, M., Tintelnot, J., Bozorgmehr, F., Pogorzelski, M., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.05.498

Pre-therapy neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio do not predict survival in patients treated with immune checkpoint inhibitors.

Mann, H., Mushtaq, M. U., Andrade-Gonzalez, X. A., Ahmed, A. T., & Gupta, S. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e15092 · Cited by 1 · see citing works